• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.

作者信息

Gupta Vikas, Harrison Claire, Hexner Elizabeth O, Al-Ali Haifa Kathrin, Foltz Lynda, Montgomery Michael, Sun William, Gopalakrishna Prashanth, Kantarjian Hagop, Verstovsek Srdan

机构信息

Princess Margaret Cancer Centre, Toronto, ON, Canada

Guy's and St Thomas' NHS Foundation, London, UK.

出版信息

Haematologica. 2016 Dec;101(12):e482-e484. doi: 10.3324/haematol.2016.151449. Epub 2016 Sep 1.

DOI:10.3324/haematol.2016.151449
PMID:27587385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5479619/
Abstract
摘要

相似文献

1
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.在COMFORT研究中，贫血对接受鲁索替尼治疗的骨髓纤维化患者总生存的影响。
Haematologica. 2016 Dec;101(12):e482-e484. doi: 10.3324/haematol.2016.151449. Epub 2016 Sep 1.
2
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.芦可替尼治疗骨髓纤维化患者的长期生存：COMFORT-I 和 -II 汇总分析。
J Hematol Oncol. 2017 Sep 29;10(1):156. doi: 10.1186/s13045-017-0527-7.
3
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib.促红细胞生成素刺激剂在接受芦可替尼治疗的骨髓纤维化患者的贫血管理中是安全有效的。
Br J Haematol. 2018 Sep;182(5):701-704. doi: 10.1111/bjh.15450. Epub 2018 Jul 9.
4
Management of Myelofibrosis-Related Cytopenias.骨髓纤维化相关血细胞减少症的治疗管理。
Curr Hematol Malig Rep. 2018 Jun;13(3):164-172. doi: 10.1007/s11899-018-0447-9.
5
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.COMFORT-II 研究的 3 年疗效、安全性和生存结果，该研究是一项比较芦可替尼与骨髓纤维化最佳可用疗法的 3 期研究。
Blood. 2013 Dec 12;122(25):4047-53. doi: 10.1182/blood-2013-02-485888. Epub 2013 Oct 30.
6
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.芦可替尼用于骨髓纤维化患者的长期治疗：来自随机、双盲、安慰剂对照3期COMFORT-I试验的5年更新数据
J Hematol Oncol. 2017 Feb 22;10(1):55. doi: 10.1186/s13045-017-0417-z.
7
Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.芦可替尼治疗对骨髓纤维化患者血红蛋白动态变化及贫血不良预后的影响。
Leuk Lymphoma. 2016 Oct;57(10):2464-7. doi: 10.3109/10428194.2016.1146950. Epub 2016 Feb 25.
8
Ruxolitinib for myelofibrosis--an update of its clinical effects.芦可替尼治疗骨髓纤维化：临床疗效的最新进展。
Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):638-45. doi: 10.1016/j.clml.2013.09.006. Epub 2013 Oct 2.
9
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.JUMP 研究的主要分析结果，这是一项 3b 期、扩大准入研究，评估了 ruxolitinib 在骨髓纤维化患者中的安全性和疗效，包括血小板计数低的患者。
Br J Haematol. 2020 Jun;189(5):888-903. doi: 10.1111/bjh.16462. Epub 2020 Feb 4.
10
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.芦可替尼与最佳可用疗法治疗骨髓纤维化的 JAK 抑制作用比较。
N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.

引用本文的文献

1
Emerging Therapeutic Approaches for Anemia in Myelofibrosis.骨髓纤维化贫血的新兴治疗方法
Curr Hematol Malig Rep. 2025 May 3;20(1):7. doi: 10.1007/s11899-025-00751-4.
2
Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib.芦可替尼治疗的骨髓纤维化患者血细胞减少和感染的真实世界管理
EJHaem. 2025 Mar 21;6(2):e70007. doi: 10.1002/jha2.70007. eCollection 2025 Apr.
3
Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib.红细胞分布宽度可能预测接受鲁索替尼治疗的原发性/继发性骨髓纤维化患者的药物性贫血及预后。
Oncol Ther. 2025 Mar;13(1):165-183. doi: 10.1007/s40487-024-00322-2. Epub 2025 Jan 17.
4
Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib.骨髓纤维化中的贫血：关注积极管理及莫洛替尼的作用
Cancers (Basel). 2024 Dec 4;16(23):4064. doi: 10.3390/cancers16234064.
5
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease.血细胞减少以及鲁索替尼早期与晚期治疗对类固醇难治性急性或慢性移植物抗宿主病患者的影响。
Bone Marrow Transplant. 2025 Jan;60(1):69-78. doi: 10.1038/s41409-024-02445-6. Epub 2024 Nov 6.
6
Evaluating estimated health care resource utilization and costs in patients with myelofibrosis based on transfusion status and anemia severity: A retrospective analysis of the Medicare Fee-For-Service claims data.基于输血状态和贫血严重程度评估骨髓纤维化患者的估算医疗资源利用和成本：对医疗保险按服务收费索赔数据的回顾性分析。
J Manag Care Spec Pharm. 2024 Dec;30(12):1395-1404. doi: 10.18553/jmcp.2024.24050. Epub 2024 Oct 3.
7
How I individualize selection of JAK inhibitors for patients with myelofibrosis.我如何为骨髓纤维化患者个体化选择JAK抑制剂。
Blood. 2025 Apr 17;145(16):1724-1737. doi: 10.1182/blood.2023022415.
8
Momelotinib in myelofibrosis and beyond: a comprehensive review of therapeutic insights in hematologic malignancies.莫洛替尼在骨髓纤维化及其他病症中的应用：血液系统恶性肿瘤治疗见解的全面综述
Discov Oncol. 2024 Aug 27;15(1):370. doi: 10.1007/s12672-024-01252-1.
9
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM.从 MOMENTUM 研究看芦可替尼对比达那唑治疗骨髓纤维化患者的输血相关费用节省和时间负担
Future Oncol. 2024;20(30):2259-2270. doi: 10.1080/14796694.2024.2368450. Epub 2024 Jul 29.
10
Management of Patients with Early Myelofibrosis: A Discussion of Best Practices.早期骨髓纤维化患者的管理：最佳实践的讨论。
Curr Hematol Malig Rep. 2024 Jun;19(3):111-119. doi: 10.1007/s11899-024-00729-8. Epub 2024 Mar 5.

本文引用的文献

1
Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.芦可替尼治疗对骨髓纤维化患者血红蛋白动态变化及贫血不良预后的影响。
Leuk Lymphoma. 2016 Oct;57(10):2464-7. doi: 10.3109/10428194.2016.1146950. Epub 2016 Feb 25.
2
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.鲁索替尼治疗骨髓纤维化的两项随机III期试验COMFORT-I和COMFORT-II中总生存期的汇总分析。
Haematologica. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11.
3
Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.芦可替尼治疗骨髓纤维化患者的血细胞减少症的管理及剂量调整对疗效结局的影响。
Onco Targets Ther. 2013 Dec 17;7:13-21. doi: 10.2147/OTT.S53348. eCollection 2013.
4
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.COMFORT-II 研究的 3 年疗效、安全性和生存结果，该研究是一项比较芦可替尼与骨髓纤维化最佳可用疗法的 3 期研究。
Blood. 2013 Dec 12;122(25):4047-53. doi: 10.1182/blood-2013-02-485888. Epub 2013 Oct 30.
5
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.芦可替尼治疗骨髓纤维化患者的疗效、安全性和生存：COMFORT-I 研究中位 2 年随访结果。
Haematologica. 2013 Dec;98(12):1865-71. doi: 10.3324/haematol.2013.092155. Epub 2013 Sep 13.
6
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.芦可替尼治疗骨髓纤维化的双盲、安慰剂对照试验。
N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.
7
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.芦可替尼与最佳可用疗法治疗骨髓纤维化的 JAK 抑制作用比较。
N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.
8
One thousand patients with primary myelofibrosis: the mayo clinic experience.一千例原发性骨髓纤维化患者：梅奥诊所的经验。
Mayo Clin Proc. 2012 Jan;87(1):25-33. doi: 10.1016/j.mayocp.2011.11.001.
9
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.DIPSS plus：一种改良的原发性骨髓纤维化动态国际预后评分系统，纳入了核型、血小板计数和输血状态的预后信息。
J Clin Oncol. 2011 Feb 1;29(4):392-7. doi: 10.1200/JCO.2010.32.2446. Epub 2010 Dec 13.
10
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.动态国际预后评分系统（DIPSS）可预测原发性骨髓纤维化进展为急性髓系白血病的情况。
Blood. 2010 Oct 14;116(15):2857-8. doi: 10.1182/blood-2010-06-293415.